Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 1:05 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 48 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Loperamide Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Bioequivalence Study of Loperamide Hydrochloride 2 mg and Simethicone 125 mg Tablet Under Fasting Conditions

NCT00778115
View directory record Official record
Conditions
Healthy
Interventions
Loperamide HCl 2 mg and simethicone 125 mg tablets
Drug
Lead sponsor
Ranbaxy Laboratories Limited
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Saint Charles, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 22, 2008 · Synced Sep 3, 2026, 1:05 AM EDT
Withdrawn Phase 3 Interventional

A Phase III Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Investigational Product MP-101 in Subjects With Short Bowel Syndrome Who Have Had an Inadequate Response to Anti-Diarrheals

NCT02242656
View directory record Official record
Conditions
Short Bowel Syndrome, Short Gut Syndrome, SBS, Short Bowel, Short Gut
Interventions
Opium Tincture USP Deodorized
Drug
Lead sponsor
Marathon Pharmaceuticals, LLC
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
5
States / cities
Chicago, Illinois • Indianapolis, Indiana • Cleveland, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2015 · Synced Sep 3, 2026, 1:05 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Safety and Efficacy of FMT in Individuals With One or More Recurrences of Clostridium Difficile Associated Disease (CDAD)

NCT03548051
View directory record Official record
Conditions
Clostridial Infection, Dysbiosis, Probiotic Therapy
Interventions
Fecal Microbiota Transplantation (FMT), Saline
Procedure · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 99 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
3
States / cities
Decatur, Georgia • Durham, North Carolina • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 1, 2022 · Synced Sep 3, 2026, 1:05 AM EDT
Completed Phase 1Phase 2 Interventional Results available

TRC102 and Temozolomide for Relapsed Solid Tumors and Lymphomas

NCT01851369
View directory record Official record
Conditions
Lymphomas, Solid Tumors, NSCLC, Metastatic Colon Carcinoma, Granulosa Cell Ovarian Cancer
Interventions
TRC102, CT scan, Lomotil, Prochlorperazine, Metoclopramide, 5-HT3 antagonist, Aprepitant, Biopsy
Drug · Diagnostic Test · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 7, 2024 · Synced Sep 3, 2026, 1:05 AM EDT
Recruiting Phase 1 Interventional

BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors

NCT06120283
View directory record Official record
Conditions
Advanced Solid Tumor, Advanced Breast Cancer, Metastatic Breast Cancer, Hormone-receptor-positive Breast Cancer, Hormone Receptor Positive Breast Carcinoma, Hormone Receptor Positive Malignant Neoplasm of Breast, HER2-negative Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer
Interventions
BGB-43395, Fulvestrant, Letrozole, Elacestrant, Anti-Diarrheal Agent
Drug
Lead sponsor
BeOne Medicines
Industry
Eligibility
18 Years and older
Enrollment
433 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
10
States / cities
Denver, Colorado • Lake Mary, Florida • Detroit, Michigan + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 3, 2026, 1:05 AM EDT
Terminated Not applicable Interventional Results available

Zemedy Application for Irritable Bowel Syndrome

NCT04723056
View directory record Official record
Conditions
IBS - Irritable Bowel Syndrome
Interventions
Use of Zemedy Application
Device
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Redwood City, California
Source: ClinicalTrials.gov public record
Updated May 27, 2025 · Synced Sep 3, 2026, 1:05 AM EDT
Active, not recruiting Phase 1 Interventional Results available

Selinexor (KPT-330) in Combination With Temozolomide and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma

NCT04216329
View directory record Official record
Conditions
Gliosarcoma, Newly Diagnosed, Glioblastoma
Interventions
Selinexor, Temozolomide, Generic Radiation therapy (RT), Selective serotonin receptor (5-HT3) antagonists, Olanzapine, Salt tablets, Anti-diarrheal
Drug · Radiation · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Sep 3, 2026, 1:05 AM EDT
Terminated Phase 2 Interventional Results available

Sacituzumab Govitecan for Relapsed Ovarian, Endometrial, and Cervical Carcinomas

NCT06865677
View directory record Official record
Conditions
Recurrent Platinum Resistant Epithelial Ovarian Carcinoma, Recurrent Epithelial Endometrial Carcinoma, Recurrent Epithelial Cervical Carcinoma
Interventions
Sacituzumab Govitecan, EKG, Brain MRI, CT scans, Tumor biopsy, Loperamide, Octreotide, Diphenoxylate/Atropine, Antiemetics
Drug · Diagnostic Test · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years · Female only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Sep 3, 2026, 1:05 AM EDT
Completed Phase 1Phase 2 Interventional Results available

E7 TCR T Cells for Human Papillomavirus-Associated Cancers

NCT02858310
View directory record Official record
Conditions
Papillomavirus Infections, Cervical Intraepithelial Neoplasia, Carcinoma In Situ, Vulvar Neoplasms, Vulvar Diseases
Interventions
E7 TCR cells, Aldesleukin, Fludarabine, Cyclophosphamide, EKG, Biopsy, Chest CT and MRI or PET, PFT, Granisetron, Ondansetron, Droperidol, Prochlorperazine, Diphenoxylate HCL, Atropine sulfate, Codeine sulfate, Loperamide, Indomethacin, Acetaminophen, Diphenhydramine HCL, Hydroxyzine HCL, Meperidine
Biological · Drug · Diagnostic Test + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
2
States / cities
Bethesda, Maryland • New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 8, 2026 · Synced Sep 3, 2026, 1:05 AM EDT
Terminated Not applicable Interventional Results available

CASAD for Severe Diarrhea in the Emergency Department

NCT02018653
View directory record Official record
Conditions
Cancer, Diarrhea
Interventions
Calcium Alumina-Silicate (CASAD), Placebo, Questionnaire
Drug · Other · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 25, 2018 · Synced Sep 3, 2026, 1:05 AM EDT
Completed Phase 3 Interventional Results available

ADAM-Afatinib Diarrhea Assessment and Management

NCT01814553
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
afatinib, loperamide
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
12
States / cities
Santa Rosa, California • Orlando, Florida • Port Saint Lucie, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2016 · Synced Sep 3, 2026, 1:05 AM EDT
Not yet recruiting Phase 4 Interventional

Tirzepatide for Ileal Pouch-anal Anastomosis (IPAA) and Chronic High Bowel Frequency (I8F-NS-X008)

NCT07756359
View directory record Official record
Conditions
Pouch, Ileal, Pouches, Ileoanal, Bowel Diseases, Inflammatory
Interventions
Tirzepatide, Loperamide, Diphenoxylate/Atropine
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
5
States / cities
Beverly Hills, California • Rochester, Minnesota • St Louis, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2026 · Synced Sep 3, 2026, 1:05 AM EDT
Completed Phase 2 Interventional Results available

Calcium Aluminosilicate Anti-Diarrheal in Treating and Preventing Diarrhea in Patients With Metastatic Colorectal Cancer Receiving Irinotecan

NCT00748215
View directory record Official record
Conditions
Chemotherapeutic Agent Toxicity, Colorectal Cancer, Diarrhea
Interventions
calcium aluminosilicate anti-diarrheal, placebo
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
2
States / cities
Portland, Oregon • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 1, 2020 · Synced Sep 3, 2026, 1:05 AM EDT
Terminated Phase 3 Interventional Results available

Use of Post Operative Loperamide in Colorectal Patients After Diverting Ileostomies

NCT02263365
View directory record Official record
Conditions
Dehydration, Diverting Ileostomy, Loperamide
Interventions
Loperamide
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 19, 2017 · Synced Sep 3, 2026, 1:05 AM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

DHB Supplement Interaction Study

NCT02257879
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Not listed
Lead sponsor
National Institute of Environmental Health Sciences (NIEHS)
NIH
Eligibility
18 Years to 60 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2020
U.S. locations
1
States / cities
Research Triangle Park, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 23, 2020 · Synced Sep 3, 2026, 1:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Loperamide Grapefruit Juice Interaction PK Trial

NCT00806299
View directory record Official record
Conditions
Drug Interaction
Interventions
Loperamide / Red Grapefruit Juice, Loperamide/ White Grapefruit Juice, Loperamide / Pink Grapefruit Juice
Drug
Lead sponsor
Johnson & Johnson Consumer and Personal Products Worldwide
Industry
Eligibility
18 Years to 59 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Oct 5, 2011 · Synced Sep 3, 2026, 1:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Abemaciclib in Healthy Participants

NCT02677844
View directory record Official record
Conditions
Healthy
Interventions
Abemaciclib, Placebo, Loperamide
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 70 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
2
States / cities
Daytona Beach, Florida • Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 3, 2019 · Synced Sep 3, 2026, 1:05 AM EDT
Completed Phase 2 Interventional Results available

Sunitinib or Cediranib for Alveolar Soft Part Sarcoma

NCT01391962
View directory record Official record
Conditions
Sarcoma, Alveolar Soft Part
Interventions
Cediranib, Sunitinib, Prochlorperazine, Promethazine, Benzodiazepine, Filgrastim, Sargramostim, Lomotil, Loperamide, Vitamin B6, Aquaphor, Acetaminophen, Levothyroxine, Warfarin
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
16 Years to 120 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 1, 2026 · Synced Sep 3, 2026, 1:05 AM EDT
Recruiting Not applicable Interventional

A Bowel Management Program (Retrograde Rectal Enema) for the Treatment of Low Anterior Resection Syndrome in Rectal Cancer Patients

NCT06424522
View directory record Official record
Conditions
Low Anterior Resection Syndrome, Rectal Carcinoma
Interventions
Dietary Fiber, Enema Administration, Loperamide Hydrochloride, Physical Therapy, Questionnaire Administration, X-Ray Imaging
Dietary Supplement · Procedure · Drug + 1 more
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Sep 3, 2026, 1:05 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Rash & Diarrhea Prophylaxis With Capivasertib

NCT07426822
View directory record Official record
Conditions
Metastatic HR+/HER2- Breast Cancer
Interventions
Capivasertib, Loperamide, Fulvestrant, Ceterizine
Drug
Lead sponsor
Maryam Lustberg
Other
Eligibility
18 Years and older
Enrollment
108 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Sep 3, 2026, 1:05 AM EDT
Completed Phase 3 Interventional

Octreotide Compared With Loperamide Hydrochloride for Chemotherapy-Related Diarrhea in Patients With Colorectal Cancer

NCT00003057
View directory record Official record
Conditions
Colorectal Cancer, Diarrhea
Interventions
loperamide hydrochloride, octreotide acetate
Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years to 120 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
33
States / cities
La Jolla, California • San Francisco, California • Wilmington, Delaware + 24 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2023 · Synced Sep 3, 2026, 1:05 AM EDT
Terminated Not applicable Interventional Results available

Educational-Medical-Behavioral Treatment of Fecal Incontinence

NCT01717456
View directory record Official record
Conditions
Fecal Incontinence
Interventions
Education, Fiber supplements, Laxatives or anti-diarrheals, Pelvic floor muscle exercises, Tips on how to prevent fecal incontinence, Daily diary, Protective pads or garments
Other · Dietary Supplement · Drug + 1 more
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 16, 2017 · Synced Sep 3, 2026, 1:05 AM EDT
Completed Not applicable Interventional Results available

Effects of an Anal Insert Device in Fecal Incontinence

NCT03898778
View directory record Official record
Conditions
Fecal Incontinence
Interventions
Minnesota Medical Technologies Anal Insert Device
Device
Lead sponsor
Minnesota Medical Technologies
Industry
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 21, 2025 · Synced Sep 3, 2026, 1:05 AM EDT
Completed Phase 2 Interventional Results available

A Neoadjuvant Study of Abemaciclib (LY2835219) in Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Breast Cancer

NCT02441946
View directory record Official record
Conditions
Breast Cancer, Hormone Receptor Positive Tumor, Early-Stage Breast Carcinoma
Interventions
Abemaciclib, Loperamide, Anastrozole
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Female only
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
27
States / cities
Bakersfield, California • La Jolla, California • Los Angeles, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2020 · Synced Sep 3, 2026, 1:05 AM EDT